Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.895 CHF
−61.98 M CHF
7.04 M CHF
32.99 M
About MOLECULAR PARTNERS N
Sector
Industry
CEO
Patrick Amstutz
Website
Headquarters
Schlieren
Founded
2004
ISIN
CH0256379097
FIGI
BBG0076L94Q5
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 6ML is 4.964 CHF — it has increased by 3.77% in the past 24 hours. Watch MOLECULAR PARTNERS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange MOLECULAR PARTNERS stocks are traded under the ticker 6ML.
6ML stock has fallen by −0.96% compared to the previous week, the month change is a −9.32% fall, over the last year MOLECULAR PARTNERS has showed a 24.82% increase.
We've gathered analysts' opinions on MOLECULAR PARTNERS future price: according to them, 6ML price has a max estimate of 17.00 CHF and a min estimate of 4.50 CHF. Watch 6ML chart and read a more detailed MOLECULAR PARTNERS stock forecast: see what analysts think of MOLECULAR PARTNERS and suggest that you do with its stocks.
6ML stock is 0.66% volatile and has beta coefficient of −0.64. Track MOLECULAR PARTNERS stock price on the chart and check out the list of the most volatile stocks — is MOLECULAR PARTNERS there?
Today MOLECULAR PARTNERS has the market capitalization of 180.63 M, it has decreased by −1.03% over the last week.
Yes, you can track MOLECULAR PARTNERS financials in yearly and quarterly reports right on TradingView.
MOLECULAR PARTNERS is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
6ML earnings for the last quarter are −0.49 CHF per share, whereas the estimation was −0.54 CHF resulting in a 9.26% surprise. The estimated earnings for the next quarter are −0.39 CHF per share. See more details about MOLECULAR PARTNERS earnings.
MOLECULAR PARTNERS revenue for the last quarter amounts to 700.00 K CHF, despite the estimated figure of 350.00 K CHF. In the next quarter, revenue is expected to reach 200.00 K CHF.
6ML net income for the last quarter is −16.40 M CHF, while the quarter before that showed −15.08 M CHF of net income which accounts for −8.77% change. Track more MOLECULAR PARTNERS financial stats to get the full picture.
No, 6ML doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 182.00 employees. See our rating of the largest employees — is MOLECULAR PARTNERS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MOLECULAR PARTNERS EBITDA is −60.67 M CHF, and current EBITDA margin is −833.87%. See more stats in MOLECULAR PARTNERS financial statements.
Like other stocks, 6ML shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MOLECULAR PARTNERS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MOLECULAR PARTNERS technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MOLECULAR PARTNERS stock shows the neutral signal. See more of MOLECULAR PARTNERS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.